Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Future Directions in Diagnosis and Treatment of Glioblastoma
share announcement

Future Directions in Diagnosis and Treatment of Glioblastoma

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 3873

Special Issue Editors

Dr. Giuseppe Roberto Giammalva

E-Mail Website
Guest Editor
Unit of Neurosurgery, Department of Biomedicine Neurosciences and Advanced Diagnostics, School of Medicine, University of Palermo, 90100 Palermo, Italy
Interests: neuroncology; neurosonology; brain tumor surgery; neuroanatomy; IOUS; awake surgery; connectomics
Special Issues, Collections and Topics in MDPI journals
Dr. Rosa Maria Gerardi

E-Mail Website
Guest Editor
Neurosurgical Clinic AOUP “Paolo Giaccone”, Post Graduate Residency Program in Neurologic Surgery, Department of Biomedicine Neurosciences and Advanced Diagnostics, School of Medicine, University of Palermo, 90127 Palermo, Italy
Interests: neuroncology; brain tumor surgery; neuroanatomy; transphenoidal surgery
Dr. Gianluca Scalia

E-Mail Website1 Website2
Guest Editor
Neurosurgery Unit, Department of Head and Neck Surgery, Garibaldi Hospital, Catania, Italy
Interests: spine surgery; neuro-oncology; neuroanatomy; CSF disorders
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Glioblastoma (GBM) represents a challenging disease, which still harbors a very poor prognosis and limited overall survival. The combination of surgery, chemotherapy, and radiotherapy still represents the most effective treatment to prolong the limited overall survival of GBM patients. However, the treatment of GBM is characteristically hampered by two additional factors: GBM also manifests as a neurological disease, and the effectiveness of surgery depends not only on the extent of but also on the maximal safety of a resection.

According to this evidence, the treatment of GBM represents a holistic and integrated path of care made of preclinical advancements, advanced diagnostics, pre- and intraoperative techniques aimed to assess brain connectivity and improve surgical outcomes, and postoperative integrated care, from oncological therapy to supportive treatments, until the end of life of GBM patients.

The aim of this Special Issue is to focus on the current knowledge on and future directions in the biology, diagnosis, and treatment of GBM. Current hurdles, the latest advancements, and future perspectives concerning the neurobiology of GBM, advanced diagnostics, intraoperative tools and techniques, postoperative care, chemotherapy, radiotherapy, and the supportive as well as palliative care of patient with GBM will be discussed.

This Special Issue solicits preclinical and clinical original articles, literature reviews, and meta-analyses focusing on the holistic and comprehensive management of GBM, from its molecular aspects to patients’ end of life, along with diagnosis, surgical, and medical treatments. Papers focusing on molecular neurobiology, brain connectivity, neuromonitoring, brain mapping, pathological anatomy, and advanced diagnostics are also welcome.

Dr. Giuseppe Roberto Giammalva
Dr. Rosa Maria Gerardi
Dr. Gianluca Scalia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glioblastoma
  • brain tumor surgery
  • neurosurgery
  • advanced diagnostics
  • molecular biology
  • brain connectivity
  • supportive care

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

28 pages, 38233 KiB  
Article
Olea europaea Leaf Phenolics Oleuropein, Hydroxytyrosol, Tyrosol, and Rutin Induce Apoptosis and Additionally Affect Temozolomide against Glioblastoma: In Particular, Oleuropein Inhibits Spheroid Growth by Attenuating Stem-like Cell Phenotype
by Melis Ercelik, Cagla Tekin, Gulcin Tezcan, Secil Ak Aksoy, Ahmet Bekar, Hasan Kocaeli, Mevlut Ozgur Taskapilioglu, Pınar Eser and Berrin Tunca
Life 2023, 13(2), 470; https://doi.org/10.3390/life13020470 - 08 Feb 2023
Cited by 6 | Viewed by 1516
Abstract
The effects of Olea europaea leaf extract (OLE) phenolics, including oleuropein (OL), hydroxytyrosol (HT), tyrosol (TYR), and rutin against glioblastoma (GB), independently and in combination with temozolomide (TMZ), were investigated in T98G and A172 cells. Cell growth was assessed by WST-1, real-time cell [...] Read more.
The effects of Olea europaea leaf extract (OLE) phenolics, including oleuropein (OL), hydroxytyrosol (HT), tyrosol (TYR), and rutin against glioblastoma (GB), independently and in combination with temozolomide (TMZ), were investigated in T98G and A172 cells. Cell growth was assessed by WST-1, real-time cell analysis, colony formation, and cell cycle distribution assays. A dual acridine orange propidium iodide (AO/PI) staining and annexin V assay determined cell viability. A sphere-forming assay, an intracellular oxidative stress assay, and the RNA expression of CD133 and OCT4 investigated the GB stem-like cell (GSC) phenotype. A scratch wound-healing assay evaluated migration capacity. OL was as effective as OLE in terms of apoptosis promotion (p < 0.001) and GSC inhibition (p < 0.001). HT inhibited cell viability, GSC phenotype, and migration rate (p < 0.001), but its anti-GB effect was less than the total effect of OLE alone. Rutin decreased reactive oxygen species production and inhibited colony formation and cell migration (p < 0.001). TYR demonstrated the least effect. The additive effects of OL, HT, TYR and rutin with TMZ were significant (p < 0.001). Our data suggest that OL may represent a novel therapeutic approach against GB cells, while HT and rutin show promise in increasing the efficacy of TMZ therapy. Full article
(This article belongs to the Special Issue Future Directions in Diagnosis and Treatment of Glioblastoma)
►▼ Show Figures

Figure 1

18 pages, 1577 KiB  
Article
Studies on Biological and Molecular Effects of Small-Molecule Kinase Inhibitors on Human Glioblastoma Cells and Organotypic Brain Slices
by Julia Hörnschemeyer, Timo Kirschstein, Gesine Reichart, Christin Sasse, Jakob Venus, Anne Einsle, Katrin Porath, Michael Linnebacher, Rüdiger Köhling and Falko Lange
Life 2022, 12(8), 1258; https://doi.org/10.3390/life12081258 - 17 Aug 2022
Cited by 3 | Viewed by 1878
Abstract
Glioblastoma is the most common and aggressive primary brain tumor. Multiple genetic and epigenetic alterations in several major signaling pathways—including the phosphoinositide 3-kinases (PI3K)/AKT/mTOR and the Raf/MEK/ERK pathway—could be found. We therefore aimed to investigate the biological and molecular effects of small-molecule kinase [...] Read more.
Glioblastoma is the most common and aggressive primary brain tumor. Multiple genetic and epigenetic alterations in several major signaling pathways—including the phosphoinositide 3-kinases (PI3K)/AKT/mTOR and the Raf/MEK/ERK pathway—could be found. We therefore aimed to investigate the biological and molecular effects of small-molecule kinase inhibitors that may interfere with those pathways. For this purpose, patient-derived glioblastoma cells were challenged with dactolisib, ipatasertib, MK-2206, regorafenib, or trametinib. To determine the effects of the small-molecule kinase inhibitors, assays of cell proliferation and apoptosis and immunoblot analyses were performed. To further investigate the effects of ipatasertib on organotypic brain slices harboring glioblastoma cells, the tumor growth was estimated. In addition, the network activity in brain slices was assessed by electrophysiological field potential recordings. Multi-kinase inhibitor regorafenib and both MK-2206 and dactolisib were very effective in all preclinical tumor models, while with respect to trametinib, two cell lines were found to be highly resistant. Only in HROG05 cells, ipatasertib showed anti-tumoral effects in vitro and in organotypic brain slices. Additionally, ipatasertib diminished synchronous network activity in organotypic brain slices. Overall, our data suggest that ipatasertib was only effective in selected tumor models, while especially regorafenib and MK-2206 presented a uniform response pattern. Full article
(This article belongs to the Special Issue Future Directions in Diagnosis and Treatment of Glioblastoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop